📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Epigenomics

1.1 - Company Overview

Epigenomics Logo

Epigenomics

Headquarter: Germany
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of molecular diagnostics, developing and commercializing in vitro cancer diagnostic tests to detect cancer at early stages using body fluids such as blood plasma; offerings include Epi proColon, a blood test for colorectal cancer.

Products and services

  • In Vitro Cancer Diagnostic Test Development: Develops in vitro cancer tests that find cancers at early stages before symptoms, carried out on body fluids such as blood plasma
  • Molecular Diagnostics Manufacturing & Commercialization: Fabricates and commercializes diagnostic tests for cancer, producing a pipeline for diagnosis performed on body fluids, such as blood plasma, aiming early detection
  • Epi proColon: A blood-based diagnostic test designed for detection of colorectal cancer, enabling early-stage identification before symptoms occur, performed conveniently on body fluids such as blood plasma

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Epigenomics

Wugen Logo

Wugen

HQ: United States Website
  • Description: Provider of off-the-shelf allogeneic cellular therapies for solid tumors and hematologic malignancies, including WU-NK-101, a memory NK cell therapy, and WU-CART-007, a CD7-targeting CAR-T for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; plus Memory NK and CAR-T platforms enabling feeder-free cryopreserved NK cells and donor-derived CAR-T cells engineered to reduce fratricide and Graft vs. Host Disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Wugen company profile →
Zionexa Logo

Zionexa

HQ: United States Website
  • Description: Provider of in-vivo biomarkers developed and commercialized to guide targeted therapies in oncology, aiming to improve patients' pathway and quality of life.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Zionexa company profile →
Biothera Logo

Biothera

HQ: United States Website
  • Description: Provider of biotechnology developing natural gluco polysaccharides that engage and direct natural innate immune systems.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Biothera company profile →
Circio Logo

Circio

HQ: Norway Website
  • Description: Provider of active immunotherapy cancer vaccines for post-operation treatments, including TG01, a peptide-based vaccine targeting KRAS/RAS driver mutations in clinical trials for RAS-mutated pancreatic cancer, lung cancer, and multiple myeloma, and circVec, a genetic medicine platform producing multifunctional circular RNA from DNA and viral vectors with enhanced, durable protein expression versus classic mRNA systems.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Circio company profile →
ProfoundBio Logo

ProfoundBio

HQ: United States Website
  • Description: Provider of antibody-based cancer therapeutics, including antibody-drug conjugates. Clinical-stage pipeline includes Rina-S, a folate receptor alpha-targeting ADC for ovarian and other solid tumors (Phase 2); PRO1160, a CD70-targeting ADC for solid tumors and hematological malignancies (Phase 1/2); PRO1107, a PTK7-targeted ADC with a hydrophilic MMAE-based linker-drug (Phase 1/2); and PRO1286, a bispecific EGFR/cMET ADC (trials anticipated in 2024).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ProfoundBio company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Epigenomics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Epigenomics

2.2 - Growth funds investing in similar companies to Epigenomics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Epigenomics

4.2 - Public trading comparable groups for Epigenomics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Epigenomics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Epigenomics

What does Epigenomics do?

Epigenomics is a provider of molecular diagnostics, developing and commercializing in vitro cancer diagnostic tests to detect cancer at early stages using body fluids such as blood plasma; offerings include Epi proColon, a blood test for colorectal cancer.

Who are Epigenomics's competitors?

Epigenomics's competitors and similar companies include Wugen, Zionexa, Biothera, Circio, and ProfoundBio.

Where is Epigenomics headquartered?

Epigenomics is headquartered in Germany.

How many employees does Epigenomics have?

Epigenomics has 1,000 employees 🔒.

When was Epigenomics founded?

Epigenomics was founded in 2010 🔒.

What sector and industry vertical is Epigenomics in?

Epigenomics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Epigenomics

Who are the top strategic acquirers in Epigenomics's sector and industry

Top strategic M&A buyers and acquirers in Epigenomics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Epigenomics?

Top strategic M&A buyers groups and sectors for Epigenomics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Epigenomics's sector and industry vertical

Which are the top PE firms investing in Epigenomics's sector and industry vertical?

Top PE firms investing in Epigenomics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Epigenomics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Epigenomics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Epigenomics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Epigenomics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Epigenomics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Epigenomics?

The key public trading comparables and valuation benchmarks for Epigenomics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Epigenomics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Epigenomics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Epigenomics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Epigenomics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Epigenomics's' sector and industry vertical?

Access recent funding rounds and capital raises in Epigenomics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Epigenomics